R S Hotchkiss, I E Karl. Show Affiliations »
Abstract
Mesh: See more » AnimalsAntigens, CD/therapeutic useCritical Care/methodsDisease Models, AnimalDrug Therapy, CombinationHumansImmunotherapy/methodsInflammationInterleukin 1 Receptor Antagonist ProteinInterleukin-1/antagonists & inhibitorsMiceReceptors, Tumor Necrosis Factor/therapeutic useReceptors, Tumor Necrosis Factor, Type ISepsis/drug therapySepsis/immunologySialoglycoproteins/therapeutic useTreatment OutcomeTumor Necrosis Factor-alpha/antagonists & inhibitors
Substances: See more » Antigens, CDIL1RN protein, humanIl1rn protein, mouseInterleukin 1 Receptor Antagonist ProteinInterleukin-1Receptors, Tumor Necrosis FactorReceptors, Tumor Necrosis Factor, Type ISialoglycoproteinsTumor Necrosis Factor-alpha
Year: 2001 PMID: 11373443 DOI: 10.1097/00003246-200103000-00040
Source DB: PubMed Journal: Crit Care Med ISSN: 0090-3493 Impact factor: 7.598